We Might See A Profit From Venus Medtech (Hangzhou) Inc. (HKG:2500) Soon
We feel now is a pretty good time to analyse Venus Medtech (Hangzhou) Inc.'s (HKG:2500) business as it appears the company may be on the cusp of a considerable accomplishment. Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company’s loss has recently broadened since it announced a CN¥408m loss in the full financial year, compared to the latest trailing-twelve-month loss of CN¥464m, moving it further away from breakeven. As path to profitability is the topic on Venus Medtech (Hangzhou)'s investors mind, we've decided to gauge market sentiment. We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.
Expectations from some of the Hong Kong Medical Equipment analysts is that Venus Medtech (Hangzhou) is on the verge of breakeven. They expect the company to post a final loss in 2025, before turning a profit of CN¥2.0m in 2026. The company is therefore projected to breakeven around a year from now or less! We calculated the rate at which the company must grow to meet the consensus forecasts predicting breakeven within 12 months. It turns out an average annual growth rate of 173% is expected, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected.
Given this is a high-level overview, we won’t go into details of Venus Medtech (Hangzhou)'s upcoming projects, however, take into account that typically a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.
See our latest analysis for Venus Medtech (Hangzhou)
Before we wrap up, there’s one aspect worth mentioning. The company has managed its capital prudently, with debt making up 11% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.
Next Steps:
This article is not intended to be a comprehensive analysis on Venus Medtech (Hangzhou), so if you are interested in understanding the company at a deeper level, take a look at Venus Medtech (Hangzhou)'s company page on Simply Wall St. We've also compiled a list of key aspects you should further research:
- Historical Track Record: What has Venus Medtech (Hangzhou)'s performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Venus Medtech (Hangzhou)'s board and the CEO’s background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.